Novavax Vaccine 89 Percent Effective in the U.K.
|
02/05/2021 |
U.K. Prime Minister Boris Johnson |
 Novavax recently reported on the efficacy of their innovative vaccine in a Phase-3 trial in the U.K. The Novavax product comprises synthesized components of the spike protein of SARS-CoV-2 virus in a proprietary nano-particle suspension. Novavax immunization requires two doses 21 days apart.
A total of 56 confirmed cases were observed in the placebo group and 6 cases among the vaccinates over 15,000 participants, providing an overall efficacy of 89.3 percent. The vaccine was 85.6 percent effective against the U.K. variant B.1.1.7 but was only 50 percent effective against the B.1351variant present in the Republic of South Africa. As with other vaccine manufacturers, Novavax is considering tweaking vaccines to be more effective against the South African and Brazilian P.1 variants.
|
| The U.S. Government has ordered 100 million doses of the Novavax product at a cost of $1.6 billion to be delivered during 2021, subject to FDA Emergency Use Authorization. A late-stage trial involving 30,000 volunteers was initiated in December in the U.S. and Mexico.
|
|
|
|